Format

Send to

Choose Destination
Pediatr Infect Dis J. 1997 Jan;16(1):130-3; discussion 133-4, 160-2.

Ciprofloxacin safety in a pediatric population.

Author information

1
Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA 02173, USA.

Abstract

OBJECTIVE:

We conducted a retrospective study primarily to estimate the risk of musculoskeletal toxicities associated with ciprofloxacin administration in a pediatric population. In addition risks of hepatic and renal disorders associated with ciprofloxacin therapy were calculated.

METHODS:

Adverse events in this study were restricted to those that required physician referral or hospitalization and occurred within 45 days of receiving a prescription for ciprofloxacin. From 2 resource databases, > 1700 patients < or = 17 years who received at least 1 ciprofloxacin prescription were identified between January, 1988, and December, 1993.

RESULTS:

In this population there were no cases of newly diagnosed acute arthritis or serious liver or kidney disease that were likely ciprofloxacin-induced. One patient was diagnosed with hemolytic-uremic syndrome, which may have been exacerbated by ciprofloxacin therapy.

CONCLUSIONS:

Surveillance of ciprofloxacin usage in a pediatric population failed to demonstrate serious or unusually high rates of any adverse events, including joint toxicity.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center